Simple new prenatal blood test for early and accurate detection of major chromosomal abnormalities

Simple new prenatal blood test for early and accurate detection of major chromosomal abnormalities

Molecular Diagnostics

October 22, 2015

Multiplicom is proud to launch Clarigo™, a new CE-IVD1 non-invasive prenatal test (NIPT). This highly accurate blood test will enable genetic analysis laboratories to detect the presence or absence of major chromosomal abnormalities such as trisomy 21 (Down’s syndrome), 18 (Edwards’ syndrome) and 13 (Patau syndrome), in the fetus, as early as in the first trimester of pregnancy by analysis of the fetus’s DNA in the maternal blood.

Clarigo enables an optimal workflow for low to high throughput sample processing that further reduces the overall cost to a level that will make NIPT affordable for all pregnant women as an integral part of prenatal care.

The targeted design of Clarigo enables highly accurate trisomy calling of chromosomes 21, 18 and 13 based on only 2M reads per sample, which is several times less than for generally used shotgun approaches. Data analysis and interpretation is automated with the dedicated Clarigo™ Reporter software developed at Multiplicom and empowered by proprietary algorithms. The Clarigo Reporter further includes an intrinsic quality control assessment and provides information on the fetal fraction for each sample and optionally on fetal gender.

Directly conjugated primary antibodies for imaging and flow cytometry from Abcam!

Directly conjugated primary antibodies for imaging and flow cytometry from Abcam!

Molecular Diagnostics

Design your multicolor experiments easily with directly conjugated primaries from Abcam for all your favorite neuroscience proteins. Not only your staining will be extra fast, but you will avoid the stress of finding compatible antibodies!

Click here to ​discover the full selection of conjugated primary antibodies against neuronal and glial markers, including Alexa Fluor® dyes and fluorescent proteins.

 

August 01, 2019 More +
Cancer research and Leica Laser microdissection!

Cancer research and Leica Laser microdissection!

Molecular Diagnostics

DNA mutations lead to abnormal or missing functional proteins, which can cause cells to multiply uncontrollably and become cancerous. The extraction of pure tumor material is extremely important to understand the underlying mutation for a specific cancer type.

 

December 18, 2018 More +
Ready to make an enquiry Call us on: + 961 1 39 66 77
Or email us